Wedbush Reiterates Outperform Rating for Masimo Corp. (MASI)
Masimo Corp. (NASDAQ:MASI)‘s stock had its “outperform” rating reiterated by Wedbush in a report released on Monday. They currently have a $67.00 target price on the stock, down from their previous target price of $75.00. Wedbush’s price objective indicates a potential upside of 9.53% from the stock’s current price.
Several other research analysts have also weighed in on MASI. BTIG Research reaffirmed a “hold” rating on shares of Masimo Corp. in a research report on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $55.00 target price (up from $52.00) on shares of Masimo Corp. in a research report on Friday, August 5th. Finally, Zacks Investment Research lowered Masimo Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Masimo Corp. has a consensus rating of “Buy” and an average price target of $53.40.
Shares of Masimo Corp. (NASDAQ:MASI) opened at 61.17 on Monday. The firm’s 50-day moving average price is $58.75 and its 200-day moving average price is $54.32. Masimo Corp. has a one year low of $33.03 and a one year high of $62.00. The stock has a market capitalization of $3.04 billion, a P/E ratio of 29.54 and a beta of 0.98.
Masimo Corp. (NASDAQ:MASI) last issued its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The business had revenue of $167.60 million for the quarter, compared to analyst estimates of $165.51 million. Masimo Corp. had a return on equity of 29.42% and a net margin of 16.31%. The business’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period last year, the company posted $0.36 EPS. Equities research analysts anticipate that Masimo Corp. will post $2.14 EPS for the current fiscal year.
In other news, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $58.11, for a total transaction of $116,220.00. Following the completion of the sale, the director now directly owns 54,000 shares in the company, valued at $3,137,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anand Sampath sold 65,000 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $55.04, for a total value of $3,577,600.00. Following the sale, the chief operating officer now owns 23,171 shares of the company’s stock, valued at $1,275,331.84. The disclosure for this sale can be found here. 16.60% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. CIBC World Markets Inc. acquired a new stake in shares of Masimo Corp. during the second quarter valued at $3,955,000. Acadian Asset Management LLC increased its stake in shares of Masimo Corp. by 45,388.1% in the second quarter. Acadian Asset Management LLC now owns 122,818 shares of the company’s stock valued at $6,450,000 after buying an additional 122,548 shares in the last quarter. Independent Portfolio Consultants Inc. increased its stake in shares of Masimo Corp. by 53.6% in the second quarter. Independent Portfolio Consultants Inc. now owns 12,570 shares of the company’s stock valued at $660,000 after buying an additional 4,385 shares in the last quarter. Eqis Capital Management Inc. increased its stake in shares of Masimo Corp. by 21.5% in the second quarter. Eqis Capital Management Inc. now owns 7,012 shares of the company’s stock valued at $368,000 after buying an additional 1,241 shares in the last quarter. Finally, Capstone Asset Management Co. increased its stake in shares of Masimo Corp. by 11.1% in the second quarter. Capstone Asset Management Co. now owns 17,966 shares of the company’s stock valued at $943,000 after buying an additional 1,790 shares in the last quarter. Institutional investors own 83.97% of the company’s stock.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.